全文获取类型
收费全文 | 13925篇 |
免费 | 1433篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 195篇 |
儿科学 | 394篇 |
妇产科学 | 341篇 |
基础医学 | 1965篇 |
口腔科学 | 420篇 |
临床医学 | 1525篇 |
内科学 | 2541篇 |
皮肤病学 | 123篇 |
神经病学 | 1167篇 |
特种医学 | 464篇 |
外国民族医学 | 1篇 |
外科学 | 2213篇 |
综合类 | 331篇 |
一般理论 | 19篇 |
预防医学 | 1520篇 |
眼科学 | 348篇 |
药学 | 936篇 |
中国医学 | 16篇 |
肿瘤学 | 862篇 |
出版年
2021年 | 195篇 |
2020年 | 144篇 |
2019年 | 237篇 |
2018年 | 273篇 |
2017年 | 224篇 |
2016年 | 218篇 |
2015年 | 262篇 |
2014年 | 306篇 |
2013年 | 495篇 |
2012年 | 653篇 |
2011年 | 667篇 |
2010年 | 431篇 |
2009年 | 370篇 |
2008年 | 615篇 |
2007年 | 643篇 |
2006年 | 604篇 |
2005年 | 657篇 |
2004年 | 653篇 |
2003年 | 628篇 |
2002年 | 568篇 |
2001年 | 390篇 |
2000年 | 399篇 |
1999年 | 360篇 |
1998年 | 164篇 |
1997年 | 165篇 |
1996年 | 120篇 |
1995年 | 118篇 |
1993年 | 119篇 |
1992年 | 252篇 |
1991年 | 251篇 |
1990年 | 263篇 |
1989年 | 235篇 |
1988年 | 214篇 |
1987年 | 174篇 |
1986年 | 232篇 |
1985年 | 190篇 |
1984年 | 161篇 |
1983年 | 164篇 |
1982年 | 124篇 |
1981年 | 111篇 |
1980年 | 132篇 |
1979年 | 164篇 |
1978年 | 141篇 |
1977年 | 137篇 |
1976年 | 110篇 |
1975年 | 135篇 |
1974年 | 145篇 |
1973年 | 147篇 |
1972年 | 112篇 |
1971年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
3.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
4.
5.
6.
7.
8.
9.
10.
Venom from the scorpion Pandinus imperator potently and selectively blocks voltage-gated K+ channels in bullfrog neurones (Pappone, P. A. and Cahalan, M. D. 1987, J. Neurosci. 7, 3300-3305). Its effects on neuromuscular transmission have now been assessed. Twitch tension studies on chick biventer cervicis preparations showed that the venom (1 microgram/ml and above) significantly augmented responses to nerve but not muscle stimulation; there was little change in postjunctional sensitivity to cholinoceptor agonists or K+-induced depolarization. Electrophysiological studies on mouse triangularis sterni preparations revealed that the venom had no effect on spontaneous transmitter release, but increased evoked transmitter release. Extracellular recordings of nerve terminal action potentials showed that the venom selectively reduced the component of the waveform associated with K+ currents. These results confirm that this venom can selectively block neuronal K+ currents, and they show that this can facilitate the release of acetylcholine at the neuromuscular junction. 相似文献